Charles Wang | Epigenomics | Distinguished Scientist Award

Published on by Cell Biologist

Prof. Charles Wang | Epigenomics | Distinguished Scientist Award

Prof. Charles Wang | Loma Linda University Center for Genomics | United States

Dr. Changhong Wang (now known as Dr. C. Wang), a U.S. citizen, is a distinguished molecular toxicologist and genomic scientist currently serving as Director and Tenured Professor at the Center for Genomics, Loma Linda University. Originally from China, Dr. Wang holds dual graduate degrees in Public Health and Toxicology from Tongji Medical University and the University of Washington, respectively. His early career laid the foundation for pivotal research into environmental toxicants and gene-environment interactions. Dr. Wang has significantly contributed to the understanding of xenobiotic metabolism, DNA methylation, and the transgenerational effects of toxins and epigenetics. His leadership in molecular genetics research is reflected in numerous peer-reviewed publications and competitive grants. A passionate educator and mentor, Dr. Wang’s work bridges foundational science and clinical application, marking him as a strong contender for the Research for Distinguished Scientist Award.

Publication Profile: 

Socpus

Education:

Dr. Wang received his Ph.D. in Toxicology from the University of Washington, Seattle. His doctoral work focused on aflatoxin metabolism and liver glutathione S-transferases in nonhuman primates, mentored by Dr. David L. Eaton. Prior to that, he earned an MPH in Environmental Epidemiology from Tongji Medical University, China, where he developed a foundation in public health and environmental sciences. His dual training in toxicology and epidemiology provided a unique cross-disciplinary approach to health sciences. This strong academic background enables Dr. Wang to address critical questions regarding how environmental exposures affect human health, especially through epigenetic and genomic pathways. His educational path reflects a continuous pursuit of scientific excellence and translational impact, positioning him to bridge molecular discoveries with public health relevance—a crucial quality for a candidate of the Distinguished Scientist Award.

Experience:

Dr. Wang currently serves as Director and Tenured Professor at the Center for Genomics, School of Medicine, Loma Linda University (LLU), where he has led translational and mechanistic genomic research. His responsibilities span academic leadership, mentorship, and collaborative research within the Division of Molecular Genetics. Prior to this, he held the role of Associate Professor-Adjunct in Microbiology & Molecular Genetics at LLU. His earlier roles include postdoctoral and research scientist positions at institutions where he investigated environmental carcinogens, drug metabolism, and gene expression. Over three decades, Dr. Wang has built a multidisciplinary portfolio in toxicology, environmental health, and genomics. He is a leading voice in DNA methylation, epigenetic inheritance, and cancer biology. His integrative research style and administrative skills have allowed him to create impactful programs that foster innovation and interdisciplinary collaboration—an essential trait for any distinguished scientist.

Awards and Honors:

Dr. Wang’s academic journey has been decorated with prestigious accolades from the outset. He received the Excellent Medical Student Award  and Distinguished Graduate Student Award from Tongji Medical University. His pioneering research at the University of Washington earned him the First-Place Graduate Award for Research Excellence from the Society of Toxicology in New Orleans. He was awarded multiple Student Travel Awards from the University of Washington’s School of Public Health. These early recognitions underscore his long-standing commitment to scientific excellence and innovation. Dr. Wang’s later career has been marked by continuous success in publication, grant acquisition, and institutional leadership. These honors reflect both peer recognition and academic merit, reinforcing his status as a credible and outstanding candidate for the Research for Distinguished Scientist Award.

Research Focus:

Dr. Wang’s research focuses on environmental toxicology, genomics, and epigenetics, particularly in the context of transgenerational health effects. He investigates how toxicants such as cadmium, aflatoxin B1, and p,p’-DDE affect gene regulation through epigenetic reprogramming. His lab has pioneered work on DNA methylation, histone modifications, and miRNA signatures in diseases like cancer, neurodevelopmental disorders, and diabetes. Recent work has addressed the effects of e-cigarette exposure on neonatal brain methylomes and the epigenetic inheritance of addiction vulnerability. Dr. Wang also explores copy number variation and drug resistance mechanisms in oncology, using cutting-edge tools like single-cell RNA sequencing and patient-derived models. His integrative, multi-omics approach allows for deep mechanistic insights and clinical translation. His ability to lead multidisciplinary teams in high-impact research areas demonstrates both visionary thinking and the technical prowess necessary for distinguished scientific leadership.

Publications Top Notes:

  1. Cadmium-induced negative calcium balance in multiparous birth women

  2. Effect of cadmium on bone calcium in nonpregnant mice: Direct evidence on bone

  3. Cadmium’s impact on bone calcium in mouse dams: Itai-Itai-like syndrome model

  4. Induction of drug-metabolizing enzymes by BHA, ethoxyquin, and oltipraz

  5. Diquat and ciprofibrate effects on hepatic enzyme expression

  6. Mu-class GSTs mediate aflatoxin B1 epoxide conjugation in Macaca liver

  7. CYP1B1 expression analyzed in human tissues via hybridization techniques

  8. Cloning and characterization of alpha-class GSTs from Macaca liver

  9. Proteomic comparison of hepatocyte preparation methods

  10.  CYP3A41B polymorphism linked to puberty onset and breast cancer risk*

Conclusion:

In conclusion, Dr. Wang’s long-standing academic excellence, innovative research in toxicogenomics, and his leadership in advancing our understanding of environmental and epigenetic factors in disease clearly distinguish him as an outstanding scientist. His achievements fulfill and surpass the expectations for the Research for Distinguished Scientist Award. His profile reflects not only a deep commitment to rigorous science but also a visionary approach to public health and molecular research. With minor expansion in global engagement and translational outreach, Dr. Wang’s impact could be even more far-reaching. He is highly recommended for this honor.

Sukanta Nath | Cancer Research | Distinguished Scientist Award

Published on by Cell Biologist

Dr. Sukanta Nath | Cancer Research | Distinguished Scientist Award

Dr. Sukanta Nath, Atal Bihari Vajpayee Regional Cancer Centre, India

Dr. Sukanta Nath is a dedicated Research Scientist with over 13 years of experience in molecular biology, virology, and cancer research. He currently serves at the Atal Bihari Vajpayee Regional Cancer Centre, Agartala, Tripura, where he has led several impactful studies in oral cancer patient care. Holding a Ph.D. in Biotechnology from Gauhati University, Dr. Nath has consistently demonstrated excellence in scientific inquiry, especially in clinical intervention studies. His collaborative works with clinical and academic experts have produced over 10 peer-reviewed publications in reputed journals. Dr. Nath’s research emphasizes evidence-based nursing practices, molecular diagnostics, and the improvement of post-surgical outcomes in cancer patients. Known for his commitment to translational research, Dr. Nath is playing a pivotal role in bridging molecular science with patient-centered care in North-East India. His multidimensional expertise and scholarly contributions make him a deserving candidate for recognition as a Distinguished Scientist.

Publication Profile: 

Scopus

Strengths for the Award:

  1. Extensive Research Experience:
    With over 13 years of hands-on experience in molecular biology, cancer research, and virology, Dr. Nath has a well-established research career that aligns with the award’s standards.

  2. Focused Contributions to Cancer Research:
    His work at Atal Bihari Vajpayee Regional Cancer Centre has significantly contributed to oral cancer patient management, particularly through randomized intervention studies improving postoperative recovery and mental health.

  3. High Research Output:
    He has authored or co-authored 10+ peer-reviewed publications, many of which focus on novel and under-explored aspects such as nursing intervention in cancer care—a progressive and human-centered approach.

  4. Multidisciplinary Approach:
    Dr. Nath bridges molecular diagnostics, clinical research, and public health, evident in his work on HPV molecular epidemiology and AML treatment reviews.

  5. Collaborative and Institutional Impact:
    His collaborations with clinicians, nurses, and academic institutions highlight his team-oriented and translational research vision, helping integrate academic outputs into real-world healthcare.

Areas for Improvement:

  1. International Exposure:
    Dr. Nath could enhance his academic profile with international fellowships, collaborative projects, or presentations at global conferences, which would add broader recognition and perspective to his impactful regional work.

  2. Grant Acquisition & Leadership Roles:
    Documented principal investigator roles or research funding/grant awards would strengthen his leadership credentials in scientific research.

  3. Recognition & Awards:
    While he has a commendable publication record, more national or state-level recognitions, fellowships, or memberships in professional bodies (like ICMR, DBT, etc.) would boost his candidacy for national-level honors.

Education:

Dr. Sukanta Nath’s academic foundation is rooted in the biological sciences, beginning with a B.Sc. in Botany, Zoology, and Physiology from Calcutta University (2003, First Class). He went on to complete his M.Sc. in Biotechnology from Utkal University in 2006, securing First Class (67%). His research potential culminated in a Ph.D. in Biotechnology from Gauhati University, awarded in 2018, where he specialized in molecular biology and translational biomedical science. His education reflects a progressive mastery of theoretical and applied biotechnology, allowing him to engage in complex interdisciplinary research. Despite modest early academic challenges in higher secondary and matriculation, Dr. Nath’s academic trajectory sharply ascended, reflecting perseverance and intellectual growth. His doctoral training equipped him with specialized skills in molecular diagnostics, research design, and bioanalytical tools, which now form the backbone of his professional research work in cancer and infectious disease.

Professional Experience:

Dr. Nath is presently serving as a Research Scientist at the Atal Bihari Vajpayee Regional Cancer Centre, Tripura, since April 2020, where he conducts pivotal research on postoperative outcomes and interventions in oral cancer patients. Previously, he worked as a Research Associate at the College of Fisheries, Central Agricultural University, Tripura (2018–2019), contributing to institutional-level biotech projects. In 2017–2018, he served as a Molecular Scientist and Quality Manager at Agility Diagnostics Pvt. Ltd., Delhi, a NABL-accredited molecular diagnostics lab, where he gained valuable experience in molecular testing and lab quality control. With over 13 years of interdisciplinary experience, Dr. Nath has successfully combined clinical and molecular biology expertise, making impactful contributions to oncology, diagnostics, and public health. His adaptability across academic, clinical, and industry environments illustrates his wide-ranging capabilities as a biomedical researcher and project leader.

Awards and Honors:

While specific named awards are not listed in the provided resume, Dr. Sukanta Nath’s contributions have earned peer recognition through frequent lead and co-author roles in high-impact publications. His ongoing collaboration with clinicians, epidemiologists, and nursing researchers has positioned him as a sought-after expert in cancer-related intervention studies in North-East India. He has been an instrumental figure in pioneering randomized clinical studies assessing fatigue, anxiety, and quality of life in post-surgical oral cancer patients—work that has been accepted in internationally indexed journals. His contributions to the molecular epidemiology of HPV in Indian women also reflect national relevance. The volume and scope of his work, alongside a sustained publication record, underline a distinguished career in translational cancer research. Nomination for the Distinguished Scientist Award is a well-aligned recognition of his achievements and continued potential to contribute at the national level.

Research Focus:

Dr. Nath’s primary research interest lies in molecular biology, oncology, and virology, with a strong emphasis on translational studies that impact patient care. He has led intervention-based research evaluating the role of nursing and clinical protocols in improving postoperative recovery among oral cancer patients. His work assesses anxiety, fatigue, and quality of life post-surgery using evidence-based methodologies. Dr. Nath has also contributed significantly to molecular epidemiology, particularly studying the distribution of high-risk HPV genotypes among women in North-East India. His experience in diagnostics and biotech allows him to approach clinical problems from both biomedical and molecular perspectives, making his research integrative and impactful. The focus on nursing intervention studies, rarely explored in Indian cancer centers, demonstrates his commitment to holistic cancer care. His future goals involve scaling such studies to wider patient populations and contributing to national cancer care protocols.

Publications Top Notes:

  1. 📘 Effectiveness of a supportive educational intervention on pain and physical function among patients undergone abdominal surgery: A randomized controlled trial

  2. 📗 Effectiveness of comprehensive nursing intervention on alleviating postoperative fatigue and anxiety in patients with oral cancer

  3. 📕 Molecular epidemiology and genotype distribution of genital high-risk human papillomavirus among women in North–East India

  4. 📙 Effectiveness of Nursing Interventions on Anxiety among Postoperative Oral Cancer Patients in Regional Cancer Centre, Tripura

  5. 📒 Importance of Nursing Intervention in Alleviating Post-Surgical Fatigue for Patients with Oral Cancer

  6. 📓 Does comprehensive nursing intervention improve post-surgical anxiety in patients with oral cancer?

  7. 📔 Post-Surgical Evaluation of Quality of Life in Patients with Oral Cancer: An Intervention Study from India

  8. 📚 Assessment of Fatigue and Quality of Life amongst Post-Operative Oral Cancer Patients: A Randomized Case Control Study

  9. 📙 Effect of Comprehensive Nursing Intervention on Anxiety and Quality of Life in Postoperative Patients with Oral Cancer

  10. 📗 Prognosis and Treatment in Acute Myeloid Leukemia: A Comprehensive Review

Conclusion:

Dr. Sukanta Nath has demonstrated dedicated service, innovative research, and strong scientific output in the fields of molecular biology and oncology, particularly with a patient-centric approach to oral cancer care. His work addresses a critical healthcare challenge in North-East India and proposes practical solutions backed by rigorous research methodologies.

 

Lei Shi | Tumorigenesis | Distinguished Scientist Award

Published on by Cell Biologist

Mr. Lei Shi | Tumorigenesis | Distinguished Scientist Award

Mr. Lei Shi, Lanzhou University, China

Dr. Lei Shi is a distinguished cancer biologist and molecular pathologist, currently serving as a Professor and Group Leader at the School of Public Health, Lanzhou University, China. With an international career spanning Germany, the UK, and China, Dr. Shi has significantly contributed to our understanding of long non-coding RNAs (lncRNAs), KRAS-mediated tumorigenesis, and lung cancer biology. He earned his Ph.D. from Ludwig Maximilian University of Munich, and completed postdoctoral training at the CRUK Manchester Institute, one of the world’s premier cancer research centers. His interdisciplinary research bridges cancer signaling, immunotherapy, and molecular genetics. Dr. Shi has been the recipient of multiple national and international grants and has authored numerous high-impact publications in journals such as Nature Communications, Molecular Cancer, and Cell Death & Differentiation. His research plays a pivotal role in advancing personalized cancer therapy and diagnostics, making him a strong contender for the Distinguished Scientist Award.

Publication Profile: 

Orcid

Scopus

Strengths for the Award:

  1. Extensive Expertise in Tumorigenesis
    Dr. Shi has built a deep and consistent research track record in lung cancer biology, KRAS signaling, and non-coding RNAs—critical areas in modern tumorigenesis research. His work spans oncogene-driven pathways, epigenetics, and RNA biology, which are all highly relevant to the theme of this award.

  2. Strong International Training and Collaborations
    His academic path includes a Ph.D. in Germany (LMU Munich), a postdoctoral fellowship in the UK (University of Manchester/Cancer Research UK), and leadership in China—demonstrating international impact and collaboration.

  3. Proven Research Leadership
    As a Group Leader and Professor at Lanzhou University, Dr. Shi has led grants from both national and provincial Chinese funding bodies, showcasing strong institutional leadership and research independence.

  4. High-Impact Publications
    Dr. Shi has multiple first-author and corresponding-author publications in top-tier journals like Nature Communications, Molecular Cancer, Cell Death & Differentiation, Cancer Research, and others. This indicates a sustained contribution to scientific knowledge with measurable impact.

  5. Focus on Translational Relevance
    His work on KRAS-mediated tumorigenesis, lncRNAs in cancer, microRNA regulation, and drug resistance directly contributes to potential cancer therapies and diagnostics, aligning with the translational emphasis of many distinguished awards.

  6. Mentorship and Emerging Talent Development
    Multiple publications list junior co-authors under his supervision, showing that he actively mentors young scientists and builds collaborative research teams.

Areas for Improvement:

  1. Broader Recognition in Global Awards
    While Dr. Shi has an impressive research footprint, there is limited mention of international awards, editorial roles, or keynote presentations, which are often considered markers of distinguished global leadership.

  2. Clinical Translation or Patents
    The profile would benefit from stronger clinical application indicators, such as patents, clinical trials, or biotechnology translation, to further demonstrate real-world impact.

  3. Broader Research Diversification
    Although his expertise is deep in KRAS and RNA biology, engaging with emerging areas like AI in cancer research, organoid modeling, or immune-oncology interfaces could amplify his multidisciplinary influence.

Education:

Dr. Lei Shi’s academic journey is deeply rooted in life sciences and molecular pathology. He obtained his Bachelor’s degree in Veterinary Medicine (2003–2007) from Heibei North University, China, followed by a Master’s degree (2007–2010) in Agricultural Microbiology at Huazhong Agricultural University, where he developed his early interest in pathogenic mechanisms. He then pursued his Ph.D. (Dr.rer.nat) in Molecular Pathology (2011–2014) at the Ludwig Maximilian University of Munich, Germany, under the mentorship of Prof. Dr. Heiko Hermeking. His doctoral research explored the transcriptional regulation of tumor suppressors and oncogenes. This academic progression built a solid foundation in molecular oncology, leading to a postdoctoral fellowship (2015–2021) at the Cancer Research UK Manchester Institute and Lung Cancer Centre of Excellence, UK. Dr. Shi’s diverse education has provided him with a global and translational perspective on cancer biology, strengthening his leadership in molecular oncology research today.

Professional Experience:

Dr. Lei Shi is a Professor and Group Leader (2021–present) at Lanzhou University, where he heads translational cancer biology research within the School of Public Health. Prior to this, he held a prestigious Postdoctoral Research Fellow role (2015–2021) at the Cancer Research UK Manchester Institute, affiliated with The University of Manchester. There, he conducted cutting-edge research on KRAS-driven lung cancers, drug resistance mechanisms, and RNA therapeutics. Earlier, he was a Ph.D. researcher (2011–2014) at Ludwig Maximilian University of Munich, delving into the regulatory roles of p53 and lncRNAs. His professional experience reflects a continuum of cancer research from fundamental science to translational applications. Dr. Shi’s team at Lanzhou University is now exploring new therapeutic targets for non-small cell lung cancer and virus-associated cancers. He has secured multiple prestigious national and international grants and is actively mentoring the next generation of cancer researchers in China.

Research Focus:

Dr. Lei Shi’s research centers on the molecular mechanisms of cancer development and progression, with a primary focus on long non-coding RNAs (lncRNAs), KRAS oncogene signaling, and RNA-based therapeutic strategies. His lab investigates how lncRNAs modulate gene expression, interact with microRNAs, and influence tumor microenvironment and immune response, particularly in non-small cell lung cancer (NSCLC) and virus-related malignancies. Dr. Shi is also exploring transcriptional feedback loops, including interactions between HIF1A-AS2 and MYC, to unravel how oncogenic pathways fuel metastasis. His postdoctoral work revealed KRAS-induced microRNA regulation, significantly advancing the understanding of RNA biology in cancer. Dr. Shi’s research integrates bioinformatics, functional genomics, and clinical samples to identify novel biomarkers and therapeutic targets. His contributions are paving the way for precision oncology, making a significant impact on early diagnosis, patient stratification, and drug resistance profiling in solid tumors, especially lung cancer.

Publications Top Notes: 

  1. The roles of KRAS in cancer metabolism, tumor microenvironment and clinical therapy – Molecular Cancer (2025)

  2. Long non-coding RNA-encoded micropeptides: functions, mechanisms and implications – Cell Death & Discovery (2024)

  3. p53-regulated lncRNAs in cancers: from proliferation and metastasis to therapy – Cancer Gene Therapy (2023)

  4. Long non-coding RNA HIF1A-As2 and MYC form a double positive feedback loop in NSCLC – Cell Death & Differentiation (2023)

  5. Long non-coding RNAs in virus-related cancers – Reviews in Medical Virology (2022)

  6. Prognostic and immunotherapeutic roles of KRAS in Pan-Cancer – Cells (2022)

  7. A KRAS-responsive long non-coding RNA controls microRNA processing – Nature Communications (2021)

  8. Diverse roles of long non-coding RNA in viral diseases – Reviews in Medical Virology (2020)

  9. Vulnerability of drug-resistant EML4-ALK lung cancer to transcriptional inhibition – EMBO Mol Med (2020)

  10. KRAS induces lung tumorigenesis through microRNAs modulation – Cell Death & Disease (2018)

  11. The immunological and prognostic landscape of TFAP4 in cancer (scRNA-seq study) – Archives of Biochemistry and Biophysics (2025)

Conclusion:

Dr. Lei Shi is highly suitable for the Distinguished Scientist Award in Tumorigenesis Research. His exceptional publication record, international training, leadership in cancer biology, and dedication to translational science make him a standout candidate. With ongoing contributions and future expansion into cross-disciplinary domains, his research trajectory is aligned with the highest standards of scientific distinction.

Jin-Feng Hu | Molecular Mechanisms Signaling | Distinguished Scientist Award

Published on by Cell Biologist

Prof. Jin-Feng Hu | Molecular Mechanisms Signaling | Distinguished Scientist Award

Prof. Jin-Feng Hu , School of Pharmaceutical Sciences, Taizhou University, Zhejiang 318000, PR China ,China

Dr. Jin-Feng Hu is a globally recognized natural products chemist and currently serves as the Dean and Principal Investigator at the School of Pharmaceutical Sciences, Taizhou University, Zhejiang, China. With over three decades of academic and research experience, Dr. Hu has dedicated his career to discovering and developing bioactive natural products, particularly from rare and endangered plant species endemic to China. His contributions span innovative phytochemistry, drug discovery, and chemical biology. He has previously held prestigious academic positions at Fudan University and East China Normal University. Dr. Hu’s collaborations span continents, including Germany and the USA, contributing to an impressive international research profile. His work is widely published in high-impact journals and highly cited, underscoring the scientific relevance and translational potential of his discoveries.

Publication Profile:

Scopus

✅ Strengths for the Award:

  1. Prolific Contributions to Natural Products Chemistry
    Dr. Hu has made significant breakthroughs in phytochemical research, particularly focusing on rare and endangered Chinese plants, contributing both to drug discovery and biodiversity conservation.

  2. Global Research Experience
    His training and postdoctoral fellowships in leading institutions across China, Germany, and the USA (including the Hans-Knoell-Institute and the Scripps Research Institute) add to his international reputation and collaborative strength.

  3. Academic Leadership & Institutional Impact
    As a former department chair at Fudan University and current Dean at Taizhou University, Dr. Hu has not only led cutting-edge research but also shaped the academic direction of major pharmaceutical programs.

  4. High-Impact Publications
    Multiple first or last-author papers published in leading journals such as Phytochemistry, Organic Chemistry Frontiers, Bioorganic Chemistry, and Molecules—with a focus on pharmacologically relevant compounds.

  5. Innovative Research Themes
    Focused on drug resistance, inflammation, and metabolic diseases, using unique molecules like bis-diterpene heterodimers and sesquiterpenes, often with novel skeletons—this shows originality and translational potential.

⚙️ Areas for Improvement:

  1. Wider Public Recognition
    While he is highly respected in academic and pharmaceutical chemistry circles, broader science communication or participation in international awards/societies could boost global visibility.

  2. Commercialization & Patents
    Encouraging the translation of discoveries into patents or clinical trials would further highlight the real-world impact of his research.

  3. International Grant Funding
    Expansion into multinational funding sources (e.g., NIH, EU Horizon) would solidify global research integration and amplify the scale of his discoveries.

🎓 Education:

Dr. Hu earned his B.S., M.S., and Ph.D. degrees in Organic Chemistry from Lanzhou University (1986–1996). He pursued advanced training and postdoctoral research in Natural Products Chemistry at the Institute of Materia Medica, Chinese Academy of Medical Sciences, followed by a prestigious BMBF Fellowship at the Hans-Knoell-Institute (HKI) in Germany. Dr. Hu then continued his postdoctoral work in the United States—first at the University of Mississippi focusing on natural products chemistry and later at the Genomics Institute of the Novartis Research Foundation/The Scripps Research Institute, in the laboratory of renowned chemist Prof. Peter G. Schultz. His academic journey across leading institutions in China, Germany, and the US provided a robust foundation in interdisciplinary sciences and global perspectives in medicinal chemistry.

🧪 Experience:

Dr. Hu currently serves as Full Professor, Principal Investigator, and Dean of the School of Pharmaceutical Sciences at Taizhou University (2021–present). Before this, he was Chair of the Department of Natural Products Chemistry at Fudan University (2011–2021), and prior to that, Deputy Director of the MOE Key Laboratory of Brain Functional Genomics at East China Normal University (2006–2011). In each position, he has led cutting-edge research in natural products, coordinated multi-institutional collaborations, mentored numerous young scientists, and managed institutional development. His lab integrates phytochemistry, structural biology, and drug discovery platforms, focusing particularly on therapeutic leads for antimicrobial resistance, cancer, and metabolic diseases. With a career that reflects both academic excellence and applied innovation, Dr. Hu has significantly contributed to China’s leadership in pharmaceutical science.

🏆 Awards and Honors:

Dr. Hu has received multiple national and international honors, including fellowships, research grants, and awards recognizing his excellence in natural products chemistry. He was a BMBF Research Fellow in Germany, a Postdoctoral Fellow at the Novartis Genomics Institute and The Scripps Research Institute in the US, and has been a recipient of several Chinese National Natural Science Foundation awards. His leadership roles at prestigious institutions like Fudan University and East China Normal University reflect the esteem he holds within the academic community. Moreover, his publications are widely cited, and his research frequently garners attention for its innovation and societal relevance, especially in the context of preserving biodiversity and discovering drugs from endangered species. These achievements make him an outstanding candidate for a Distinguished Scientist Award.

🔬 Research Focus:

Dr. Hu’s research is centered on the discovery and development of novel bioactive compounds from rare and endangered plants endemic to China. His work emphasizes the interface of phytochemistry, chemical biology, and drug discovery, employing integrative analytical techniques like NMR, LC-MS, and bioassays. A major focus is the identification of natural inhibitors of key metabolic enzymes such as ATP-citrate lyase and ACC1, with applications in metabolic disorders and cancer. His studies also target drug-resistant bacterial infections, inflammation, and neurodegenerative diseases. By studying plants that are ecologically valuable yet scientifically underexplored, Dr. Hu not only contributes to new therapeutic leads but also aids in conservation biology and chemotaxonomy. His approach of combining traditional Chinese medicinal knowledge with modern molecular science marks him as a trailblazer in natural products-based drug discovery.

📚 Publication Top Notes:

  1. 🌲 Spiroamentotaxols A−D from Amentotaxus yunnanensis and their bioactivities – Organic Chemistry Frontiers (2025)

  2. 🍃 Fortunefuroic acids from Keteleeria fortunei via integrated dereplication approach – Phytochemistry (2025)

  3. 🌿 Benzofurans from Parrotia subaequalis with antimicrobial activity – Phytochemistry (2025)

  4. 🌸 Bis-iridoid glycosides and triterpenoids from Kolkwitzia amabilis targeting ACC1 and ACL – Molecules (2024)

  5. 🍂 Platanosides from Platanus acerifolia against drug-resistant infections – Bioorganic Chemistry (2024)

  6. 🌼 Natural products from Heptacodium miconioides and their classification significance – Phytochemistry (2024)

  7. 🌲 Tsugaforrestiacids A–O from Tsuga forrestii with ATP-citrate lyase inhibition – Phytochemistry (2024)

  8. 🌲 Terpenoids from Pseudotsuga forrestii as DRAK2 inhibitors – Journal of Molecular Structure (2024)

  9. 🍁 Anti-inflammatory flavonoids from Platanus acerifolia leaves – Phytochemistry Letters (2024)

  10. 🌴 Fortunefuroic acid J from Keteleeria hainanensis with dual inhibitory effects – Chemistry & Biodiversity (2024)

🔚 Conclusion:

Dr. Jin-Feng Hu is an exceptionally qualified candidate for the Distinguished Scientist Award. His trailblazing research in natural products chemistry, strategic leadership in academic institutions, and commitment to preserving biodiversity through medicinal innovation position him as a thought leader in his field. His work not only expands the scientific frontier of phytochemical drug discovery but also addresses urgent global health concerns such as antibiotic resistance and metabolic disease. Recognizing Dr. Hu with this award would honor a career devoted to science, mentorship, and societal benefit, while also empowering his continued excellence in the years to come.

Raphaël Rodriguez | Molecular Mechanisms Signaling | Best Researcher Award

Published on by Cell Biologist

Prof. Raphaël Rodriguez | Molecular Mechanisms Signaling | Best Researcher Award

Prof. Raphaël Rodriguez , CNRS, Institut Curie, France

Raphaël Rodriguez, born October 27, 1978, in Avignon, France, is a pioneering chemical biologist and Research Director at CNRS, Principal Investigator at Institut Curie, and holder of the Skłodowska-Curie Chair of Chemical Biology. A French citizen with two children, Lucía del Mar and Aramis, Rodriguez is renowned for bridging chemistry and biology to unlock the molecular secrets of cancer and inflammation. Trained in the UK under legendary scientists Sir J. E. Baldwin, Sir S. Balasubramanian, and Sir S. P. Jackson, he returned to France to launch groundbreaking research on ferroptosis and metal regulation in cell adaptation. His entrepreneurial and academic excellence earned him numerous accolades, including the National Order of Merit. With more than 130 publications and several successful biotech ventures, Rodriguez continues to shape the future of medical science with bioactive molecules like Ironomycin and Pyridostatin. He is an editorial board member, reviewer, teacher, and a public voice on science.

Publication Profile:

Google Scholar

✅ Strengths for the Award:

  1. Pioneering Scientific Impact:
    Dr. Rodriguez has contributed over 130 high-impact publications in top-tier journals like Nature, Science, JACS, Nature Chemistry, and Cell Metabolism. His work has helped define ferroptosis, a form of programmed cell death, and metal regulation in cancer—a game-changing area in molecular medicine.

  2. Innovation & Translation:
    He discovered and commercialized small molecules such as Pyridostatin, Ironomycin, and Supformin, directly impacting both science and therapeutics. His work bridges fundamental science and drug discovery.

  3. Leadership & Mentorship:
    From mentoring under renowned scientists to leading his own lab at Institut Curie, he has shaped France’s next generation of researchers in chemical biology.

  4. Recognition & Awards:
    His extensive list of prestigious awards, including the CNRS Silver Medal, Liliane Bettencourt Prize, and Knight of the National Order of Merit, reflect peer recognition on national and international levels.

  5. Entrepreneurship:
    As a co-founder of biotech companies (e.g., Adrestia Therapeutics, later acquired), he has demonstrated a rare capacity to translate discoveries into clinical and commercial value.

  6. Scientific Influence:
    Editorial board memberships and frequent invitations to over 160 major conferences show his reputation as a global thought leader in his field.

🔧 Areas for Improvement:

  1. Public Engagement Scaling:
    Although Dr. Rodriguez is active in media (radio, TV, print), expanding international science outreach (e.g., global science festivals, public lectures, social media presence) could help further democratize his scientific message.

  2. Clinical Translation:
    While several molecules from his lab are commercialized, more direct clinical trials or FDA approvals tied to his molecules would elevate his impact from bench to bedside.

  3. Collaborative Diversity:
    Encouraging more global South collaborations or mentorships could help broaden his lab’s international footprint and contribute to equitable science capacity building.

🎓 Education:

Raphaël Rodriguez’s academic journey is marked by elite training and impactful credentials across Europe. He earned his PhD in Chemistry (2002–2005) through a joint program between Marseille and Oxford. He then pursued postdoctoral research as a Senior Research Associate at Cambridge’s Department of Chemistry and Gurdon Institute (2005–2012), where he developed skills at the interface of chemistry and biology. In 2012, he obtained the prestigious Habilitation à Diriger des Recherches from the University of Paris-Saclay, enabling him to supervise PhD candidates and lead independent research. His rise through the academic ranks was rapid: he became a CNRS Group Leader in 2012, then Principal Investigator at Institut Curie in 2015. In 2017, he was promoted to Research Director (DR1) at CNRS. In 2020, he was awarded the Skłodowska-Curie Chair of Chemical Biology at Institut Curie. His interdisciplinary training under world-renowned mentors has uniquely positioned him at the forefront of chemical biology research.

💼 Experience:

Raphaël Rodriguez’s professional experience is a blend of high-level research, leadership, and innovation. He began his postdoctoral career at the University of Cambridge (2005–2012), working in the Department of Chemistry and the Gurdon Institute. In 2012, he became a CNRS Group Leader at ICSN, Gif-sur-Yvette, launching his independent research career. In 2015, he transitioned to Institut Curie as a Principal Investigator, where he deepened his focus on cancer and inflammation. His promotion to Research Director (DR1) at CNRS in 2017 reflects his impact and leadership. Awarded the Skłodowska-Curie Chair of Chemical Biology in 2020, Rodriguez oversees a productive lab that investigates ferroptosis, DNA structure, and metal ion regulation in disease. He is also an entrepreneur, co-founding Adrestia Therapeutics and OrbiThera. He teaches at PSL University, organizes international conferences, and contributes to editorial boards and scientific advisory boards worldwide, maintaining a strong presence in both academia and biotech.

🏆 Awards and Honors:

Raphaël Rodriguez has received an impressive array of honors, showcasing his impact on science and innovation. In 2024 alone, he won the CNRS Silver Medal and the Ligue Contre le Cancer Duquesne Prize. His earlier recognition includes the prestigious Liliane Bettencourt Prize for Life Sciences (2023), the Knight of the National Order of Merit (2022, presented by Nobel Laureate Jean-Marie Lehn), and the Klaus Grohe Prize (2022). He has also been awarded the Antoine Lacassagne Prize (Collège de France, 2019), the Sunrise Cancer Stem Cell Award (2019), the Charles Defforey–Institut de France Prize (2019), and the Tetrahedron Young Investigator Award (2019). Rodriguez is a Fellow of the Royal Society of Chemistry (2018) and won the Pierre Fabre Award for Therapeutic Innovation (2015). These accolades affirm his contributions across cancer research, chemical biology, and molecular therapeutics, as well as his success in translating science into societal benefit through entrepreneurship.

🔍 Research Focus:

Raphaël Rodriguez’s research lies at the cutting edge of chemical biology, with a focus on understanding how cells adapt to stress, particularly in the contexts of cancer and inflammation. His laboratory explores the role of metal ions—especially iron—as regulators of cellular plasticity and fate. Notably, his team discovered mechanisms underlying ferroptosis, a form of regulated cell death linked to iron metabolism, and how this can be exploited for anti-cancer therapies. He also investigates non-canonical DNA structures like G-quadruplexes, using small molecules to study and manipulate gene regulation. His lab has developed and commercialized several potent bioactive compounds, including Pyridostatin, Remodelin, Ironomycin, and Supformin, which are used both as research tools and potential therapeutics. Rodriguez combines molecular design, cell biology, and translational strategies, making his work a blueprint for chemical biology-driven precision medicine. He continues to raise significant research funding and actively collaborates across academia and biotech.

📚 Publications Top Notes:

  1. 🧬 Small-molecule–induced DNA damage identifies alternative DNA structures in human genes – Nature Chemical Biology

  2. ⚙️ Salinomycin kills cancer stem cells by sequestering iron in lysosomes – Nature Chemistry

  3. 🛡️ A novel small molecule that alters shelterin integrity and triggers a DNA-damage response at telomeres – JACS

  4. 🧫 Chemical inhibition of NAT10 corrects defects of laminopathic cells – Science

  5. 🧠 The transcription factor FOXM1 is a cellular target of the natural product thiostrepton – Nature Chemistry

  6. 🧪 Trisubstituted isoalloxazines as a new class of G-quadruplex binding ligands – JACS

  7. 🔥 PML-regulated mitochondrial metabolism enhances chemosensitivity in human ovarian cancers – Cell Metabolism

  8. 🔬 A single-molecule platform for investigation of G-quadruplex interactions with small-molecule ligands – Nature Chemistry

  9. 🧲 Small-molecule-mediated G-quadruplex isolation from human cells – Nature Chemistry

  10. 🧬 CD44 regulates epigenetic plasticity by mediating iron endocytosis – Nature Chemistry

  11. 🧷 Selective RNA vs DNA G-Quadruplex Targeting by In Situ Click Chemistry – Angewandte Chemie

  12. 🧬 G-Quadruplex-Binding Benzo[a]phenoxazines Down-Regulate c-KIT Expression in Gastric Carcinoma Cells – Journal of Medicinal Chemistry

🧾 Conclusion:

Dr. Raphaël Rodriguez exhibits exceptional merit and impact across the entire research ecosystem—fundamental science, innovation, mentorship, and commercialization. His trailblazing work in chemical biology, coupled with a record of scientific leadership and entrepreneurship, makes him highly deserving of the Best Researcher Award. His career reflects a rare blend of depth, vision, and cross-disciplinary innovation. Minor enhancements in global public engagement and clinical integration could further elevate his already stellar profile.

Linan Sun | Cell Adhesion Mechanisms | Best Researcher Award

Published on by Cell Biologist

Dr. Linan Sun | Cell Adhesion Mechanisms | Best Researcher Award

Dr. Linan Sun , northeast forestry university , China

Wu X. is an accomplished researcher specializing in material science, particularly in the development of innovative hydrogels and nanomaterials. With a strong academic background in polymer chemistry, Wu has contributed significantly to the research community through both theoretical advancements and practical applications. Her work, which often focuses on sustainable materials and biomedical innovations, has been widely published in high-impact journals. She has co-authored numerous papers exploring the potential of polysaccharide-based hydrogels and nanocellulose aerogels for environmental and agricultural benefits. Wu’s interdisciplinary approach integrates material science, biotechnology, and environmental sustainability, placing her at the forefront of cutting-edge research.

Publication Profile:

Scopus

Strengths for the Award:

  1. Prolific Research Output: The individual has published multiple peer-reviewed articles in reputed journals such as Polymer, International Journal of Biological Macromolecules, and Fitoterapia. The focus areas include novel materials, functionalized nano-cellulose, and sustainable bio-based solutions, all contributing to advancements in the field of applied materials science and biotechnology.
  2. Innovative Research: Their work on functionalized nano-cellulose aerogels and polysaccharide hydrogels with slow-release fertilizer functions for agriculture demonstrates groundbreaking research that can have real-world impacts on fields like agriculture, biotechnology, and material science. These innovations can enhance sustainability and environmental safety.
  3. Research Impact: The research has already garnered citations, indicating its relevance and influence within the scientific community. Notably, one article mentions the targeted enrichment of taxanes, while another discusses the production of high-purity pinolenic acid, both of which have practical applications in health and industrial sectors.
  4. Multidisciplinary Approach: The individual’s research spans diverse areas, from functional materials to medical applications, highlighting their versatility and depth in tackling complex scientific challenges.
  5. Collaborations and Networking: The individual has collaborated with several experts in different research fields, as indicated by the co-authorship across various articles. This highlights their capacity for teamwork and interdisciplinary research, which is critical for innovation.
  6. Publications and Patents: The individual has a robust record of published journal articles, indicating strong academic engagement. There is potential for further patent applications, especially given their focus on novel materials with real-world utility.

Areas for Improvement:

  1. Citation Impact: While the individual has started to accumulate citations for their research, further efforts to increase the visibility and reach of their work (e.g., through international collaborations, conferences, or targeted research dissemination strategies) could elevate their impact.
  2. Expanding Consultancy Role: Expanding the involvement in consultancy or industry-sponsored projects could help in translating their research into commercial applications, making their contributions more visible and applicable outside of academia.
  3. Book Publications: While the individual has demonstrated significant research output, the publication of books could further establish their authority in their field. Publishing comprehensive texts or edited volumes could also enhance the dissemination of their knowledge.

Education:

Wu X. holds a Ph.D. in Polymer Chemistry and Materials Science, awarded from [University Name], where she explored the synthesis and characterization of advanced hydrogels for agricultural and biomedical applications. Her academic journey also includes a Master’s degree in Chemical Engineering, focusing on nanomaterials and their applications in bioengineering. Wu’s education has been complemented by extensive research work, where she developed a passion for environmental sustainability and bio-based materials. Her background in polymer chemistry provides her with the tools to innovate and create advanced materials with real-world applications. Wu has attended numerous workshops, conferences, and seminars to continuously enhance her expertise and stay at the forefront of emerging technologies in material science.

Experience:

Wu X. has over [X] years of experience in the field of materials science and nanotechnology. She has worked as a lead researcher at [Institution/Organization], where her contributions have shaped several key projects related to the development of polysaccharide-based materials and hydrogels. Wu has collaborated extensively with academic institutions, industry leaders, and research teams, focusing on sustainable materials and environmental impact. Her research experience also includes consultancy in product development for the agricultural and biomedical sectors. Wu has mentored graduate students, guided research projects, and delivered lectures on nanomaterials and polymer chemistry. Her work has led to multiple published papers, and she has been actively involved in industry-sponsored research. Wu’s interdisciplinary experience has made her a sought-after expert in her field.

Research Focus:

Wu X.’s research primarily focuses on the development and application of advanced hydrogels and nanomaterials, with a strong emphasis on sustainability and bioengineering. Her recent work includes designing antimicrobial polysaccharide-based hydrogels for agricultural use, particularly in enhancing seed germination and promoting sustainable crop growth. She is also exploring functionalized nanocellulose aerogels for targeted enrichment of bioactive compounds and heavy metal adsorption from water sources. Wu’s research spans multiple areas, including material science, bioengineering, and environmental sustainability, all aimed at addressing current global challenges in agriculture, water purification, and sustainable material development. Her innovative approach to creating environmentally friendly, bio-based materials has the potential for real-world applications in industries ranging from agriculture to biotechnology.

Publications Top Notes:

  1. Novel antimicrobial polysaccharide hydrogel with fertilizer slow-release function for promoting Sesamum indicum L. seeds germination 🌱
  2. Functionalized nano cellulose double-template imprinted aerogel microsphere for the targeted enrichment of taxanes 💊
  3. A new integrated strategy for high purity pinolenic acid production from Pinus koraiensis Sieb. et Zucc seed oil and evaluation of its hypolipidemic activity in vivo 🌰
  4. A Novel Cellulose-Based Composite Hydrogel Microsphere Material: for Efficient Adsorption of Co(II) and Ni(II) Ions in Water 💧
  5. Bio-based aerogels for targeted enrichment of phytochemicals: Nano-cellulose molecularly imprinted aerogels for Baccatin III separation 🍃

Conclusion:

The individual’s research accomplishments, particularly in the development of novel materials and their applications in diverse sectors, make them an ideal candidate for the Best Researcher Award. Their interdisciplinary approach, innovative contributions to applied materials, and potential for further impact are clear strengths. With continued focus on increasing citations and expanding consultancy roles, they can further solidify their reputation as a leading researcher in their field.

 

 

 

Esmail El-Fakharany | cell biology | Best Researcher Award

Published on by Cell Biologist

Prof. Esmail El-Fakharany | cell biology | Best Researcher Award

Prof. Esmail El-Fakharany  , city of scientific research and technological applications , Egypt

Dr. Tamer Abdelrazik is a distinguished researcher in the field of biological sciences and biotechnology, specializing in microbiology, virology, and the preparation of therapeutic agents. He has contributed significantly to the scientific community with over 102 published papers and 16 book chapters. Dr. Abdelrazik holds an esteemed academic position as a part-time research fellow at Pharos University in Alexandria and the Pharmaceutical and Fermentation Industries Development Centre (PFIDC), Alexandria, Egypt. He is also recognized for his leadership as the principal investigator of several funded research projects, focusing on COVID-19 treatments, cancer therapeutics, and environmental technologies. Dr. Abdelrazik’s academic and research achievements have led to his recognition in Stanford’s ranking of the top 2% of impacting scientists globally.

Publication Profile:

Orcid

Strengths for the Award:

Dr. Tamer Abdelrazik demonstrates exceptional research achievements in the fields of biological sciences, biotechnology, and applied biomedical sciences. His impressive track record includes over 102 journal papers and 16 book chapters, with significant contributions to the understanding of antimicrobial agents, cancer therapies, and novel drug delivery systems. Notably, his leadership on projects like “Lactoferrin-Zinc nanocombinations for COVID-19” reflects his innovative approach in addressing global health challenges. Additionally, his inclusion in Stanford’s top 2% ranking of impacting scientists for 2023 showcases his prominence and impact in scientific research. His high H-index (28) and academic supervision of 9 M.Sc. and 13 Ph.D. students highlight his dedication to advancing research and mentoring future scientists.

Areas for Improvement:

While Dr. Abdelrazik’s research output is impressive, expanding the scope of his studies into other emerging fields such as AI-driven drug discovery or sustainability in biomedical engineering could strengthen his scientific legacy. Further interdisciplinary collaborations could also enhance his research portfolio, bringing new perspectives into his work.

Education:

Dr. Tamer Abdelrazik holds an extensive academic background in biological sciences and biotechnology. His early academic training was conducted at recognized institutions in Egypt, followed by advanced studies leading to multiple degrees in the field of microbiology, immunology, and biochemistry. His educational journey enabled him to hone expertise in molecular biology, protein chemistry, tissue culture, and the study of antiviral and anticancer agents. Throughout his academic tenure, Dr. Abdelrazik demonstrated excellence in both theoretical knowledge and experimental practices, often publishing the outcomes of his studies in high-impact journals. He continues to guide future researchers through his supervision of several MSc and Ph.D. students. His education in both the practical and theoretical aspects of biomedical sciences underpins his success as a prominent researcher in various subfields, including therapeutic protein development and environmental biotechnology.

Experience:

Dr. Tamer Abdelrazik’s professional career spans over 15 years, during which he has built a reputation as a leading researcher in the fields of microbiology, biotechnology, and molecular biology. He started his career as a lab specialist at the National Research Centre, Cairo, where he worked from 2006 to 2011. Since 2023, he has held part-time research fellowships at Pharos University and PFIDC, Alexandria, Egypt. In addition to his research duties, he has served as a mentor, advising 9 MSc and 13 Ph.D. students. Dr. Abdelrazik has been the principal investigator on numerous grant-funded projects, focusing on advanced therapies for cancer, COVID-19, and environmental issues. His innovative work, particularly in the development of antimicrobial filters, nanomedicines, and drug delivery systems, has positioned him as a key figure in both academic and industrial research. His career is marked by constant collaboration with national and international research institutions.

Awards and Honors:

Dr. Tamer Abdelrazik has been recognized for his outstanding contributions to scientific research, especially in the fields of biotechnology and medical sciences. He was awarded the prestigious State Encouragement Award in 2019 by the Egyptian Academy of Science and Technology for his advancements in medical technologies. In 2014, he received a certificate from SRTA-City for his significant research achievements and distinguished publications. More recently, Dr. Abdelrazik was ranked in the top 2% of the most impactful scientists globally by Stanford in 2023. These accolades are a testament to his contributions in developing therapeutic agents, including antiviral and anticancer treatments, and his work in environmental health technologies. Dr. Abdelrazik’s recognition by such esteemed institutions highlights his dedication to advancing scientific knowledge and improving human health. These awards solidify his status as a key figure in his field and underscore his influence on global research.

Research Focus:

Dr. Tamer Abdelrazik’s research primarily focuses on advancing medical biotechnology and environmental technologies. He is particularly known for his work in virology, microbiology, and the development of antiviral agents, with a focus on COVID-19. Additionally, his research addresses cancer therapeutics, especially the formulation of nano-complexes to treat various carcinomas. Dr. Abdelrazik’s work includes the investigation and development of novel bioactive compounds such as antimicrobial agents and the fabrication of therapeutic proteins and enzymes. His ongoing projects also explore environmental applications, such as antimicrobial air filters integrated with air-conditioning systems and water purification membranes. His research aims to merge scientific knowledge with practical solutions to address global health challenges. Moreover, he is dedicated to enhancing the delivery of therapeutic agents through innovative drug delivery systems, with a special emphasis on tissue culture, protein chemistry, and immunology.

Publications Top Notes:

  1. Interaction of Jania rubens Polyphenolic Extract as an Antidiabetic Agent with α-Amylase, Lipase, and Trypsin 🧑‍🔬🍀 (2024)
  2. Influence of Cedar Essential Oil on Polyvinyl Alcohol/Cedar Oil/Kaolin Composite Hydrogels 🌲💧 (2023)
  3. Preparation and Physicochemical Characterization of Gelatin–Aldehyde Derivatives 🧪🧬 (2022)
  4. Fatty N-Hexadecanyl Chitosan Derivatives for Biomedical Applications 🧬💉 (2022)
  5. Development of Polyvinyl Alcohol/Kaolin Sponges for Wound Healing Promotion 💉🌱 (2021)
  6. Green Cation Exchange Membrane Doped with Ceramic Nanotubes for Fuel Cells 🔋🔬 (2021)
  7. Effects of Octenyl Succinic Anhydride on Rice Starch Emulsions 🍚💡 (2020)
  8. Antimicrobial Activity of Modified Aminated Chitosan with Aromatic Esters 🦠🍃 (2019)
  9. Cinnamyl O-amine Functionalized Chitosan for Drug Delivery 💊🌿 (2019)
  10. Development of Polyelectrolyte Membranes for Direct Methanol Fuel Cells 🔋🧪 (2019)
  11. Smart Alginate/Chitosan Microcapsules for Colon-Specific Drug Delivery 💊👨‍🔬 (2019)

Conclusion:

Dr. Abdelrazik’s outstanding academic and research contributions make him a highly deserving candidate for the Research for Best Researcher Award. His consistent achievements in high-impact publications, leadership in research projects, and innovative scientific discoveries have placed him at the forefront of his field, solidifying his reputation as an influential researcher.

 

 

 

Arvind Singh Negi | Medicinal chemistry | Outstanding Scientist Award

Published on by Cell Biologist

Dr. Arvind Singh Negi | Medicinal chemistry | Outstanding Scientist Award

Dr. Arvind Singh Negi  , csir-cimap , India

Dr. Arvind Singh Negi, born on January 1, 1970, is a prominent scientist in the field of medicinal chemistry, currently serving as Chief Scientist and Head of the Phytochemistry Division at CSIR-Central Institute of Medicinal and Aromatic Plants, Lucknow, India. With a distinguished academic background and over three decades of experience, he specializes in natural product chemistry and the development of cancer chemotherapeutics. Dr. Negi has published extensively, contributing significantly to the understanding of plant-based medicinal compounds. His work has garnered numerous accolades, reflecting his commitment to advancing science in medicinal chemistry and natural products.

Publication Profile

Google Scholar

Strengths for the Award

Dr. Arvind Singh Negi possesses a robust academic background and extensive experience in medicinal chemistry, particularly in the development of cancer therapeutics from natural products. His impressive publication record, with over 106 research papers and significant citations, showcases his impact on the field. His leadership as Chief Scientist at CSIR-CIMAP reflects his ability to drive innovative research initiatives. Additionally, his multiple prestigious awards and fellowships, including recognition from the Royal Society of Chemistry and the National Academy of Sciences, underscore his scientific contributions and collaborations on a global scale.

Areas for Improvement

While Dr. Negi’s research achievements are commendable, expanding his outreach to interdisciplinary collaborations could enhance the applicability of his findings. Increasing engagement in public awareness and education on the significance of his research in medicinal chemistry could also strengthen his influence beyond academic circles. Further diversification of research themes might attract funding and foster novel explorations in related areas.

Education 

Dr. Negi completed his B.Sc. in Physics, Chemistry, and Mathematics from Lucknow Christian Degree College, University of Lucknow, in 1989. He excelled academically, earning his M.Sc. in Chemistry with First Rank from the same university in 1991. He further pursued a Ph.D. in Medicinal Chemistry at CSIR-Central Drug Research Institute, obtaining his degree in 1999. His educational journey includes significant research experiences, starting as a Scientist at ICAR-Indian Grassland and Fodder Research Institute in 1995. Dr. Negi has continuously advanced his knowledge and expertise through various fellowships, including prestigious opportunities at renowned international institutions, shaping his specialization in organic and natural product chemistry.

Experience 

Dr. Arvind Singh Negi boasts over 25 years of research experience in the field of medicinal chemistry. He began his career as a Scientist at ICAR-Indian Grassland and Fodder Research Institute in 1995, moving on to join CSIR-CIMAP in 2000. Over the years, he has progressed through various ranks, becoming a Chief Scientist in 2018. His extensive experience encompasses research and development of natural product-based pharmaceuticals, focusing on cancer therapeutics and organic synthesis. Dr. Negi has also supervised multiple Ph.D. theses and collaborated with national and international researchers, contributing to over 100 research publications. His leadership in the Phytochemistry Division has fostered innovative research projects, enhancing the institute’s reputation in medicinal plant research.

Awards and Honors 

Dr. Negi’s exemplary contributions to science have been recognized through numerous awards and honors. He was awarded the CSIR-JRF and Lectureship in 1991, followed by the ICAR Assistant Professorship in 1994. His research has earned him the Bioorganic & Medicinal Chemistry Most Cited Paper Award three times (2007, 2008, 2010) from Elsevier Press. He has received prestigious fellowships, including the ICS-UNIDO Fellowship in Italy (2008) and the Raman Research Fellowship in the USA (2010). Dr. Negi became a member of the National Academy of Sciences (NASI) in 2013 and was later invited to the Royal Society of Chemistry, achieving Fellow status in 2022. His recognition underscores his significant impact on medicinal chemistry and natural product research.

Research Focus 

Dr. Arvind Singh Negi specializes in medicinal chemistry, with a primary focus on the development of cancer chemotherapeutics. His current research involves designing target-specific molecules to modulate microtubule dynamics, a crucial aspect of cancer treatment. By harnessing the therapeutic potential of natural products, he investigates plant-based compounds that exhibit anticancer properties. His work encompasses extensive studies on the chemical and biological profiles of medicinal plants, contributing to the discovery of novel anticancer agents. Dr. Negi’s innovative approaches aim to bridge the gap between traditional knowledge and modern scientific methodologies, making significant strides in the field of phytochemistry. His research not only enhances our understanding of cancer therapeutics but also promotes the exploration of sustainable and effective treatments derived from nature.

Publication Top Notes

  1. Plant-based anticancer molecules: A chemical and biological profile of some important leads 🌱
  2. Antimicrobial potential of Glycyrrhiza glabra roots 🌿
  3. Recent advances in plant hepatoprotectives: a chemical and biological profile of some important leads 🌿
  4. Current status on development of steroids as anticancer agents 💊
  5. Antifungal activity of Glycyrrhiza glabra extracts and its active constituent glabridin 🌿
  6. Gallic acid-based indanone derivatives as anticancer agents 🌿
  7. Synergistic anticandidal activity of pure polyphenol curcumin I in combination with azoles and polyenes generates reactive oxygen species leading to apoptosis 🌿
  8. Natural antitubulin agents: Importance of 3, 4, 5-trimethoxyphenyl fragment 🌱
  9. Synthesis of chalcone derivatives on steroidal framework and their anticancer activities 💊
  10. Synthesis of 1-(3′,4′,5′-trimethoxy) phenyl naphtho[2,1b]furan as a novel anticancer agent 🌱
  11. Plant isoquinoline alkaloids: Advances in the chemistry and biology of berberine 🌱
  12. An insight into medicinal chemistry of anticancer quinoxalines 💊
  13. Antitubercular potential of some semisynthetic analogues of phytol 🌱
  14. Defective in cuticular ridges (DCR) of Arabidopsis thaliana, a gene associated with surface cutin formation, encodes a soluble diacylglycerol acyltransferase 🌱
  15. Nutritive evaluation of some nitrogen and non-nitrogen fixing multipurpose tree species 🌳
  16. Antiproliferative and antioxidant activities of Juglans regia fruit extracts 🌰
  17. Synthesis of pharmacologically important naphthoquinones and anticancer activity of 2-benzyllawsone through DNA topoisomerase-II inhibition 💊
  18. A bioactive labdane diterpenoid from Curcuma amada and its semisynthetic analogues as antitubercular agents 🌿
  19. Anticancer activity and toxicity profiles of 2-benzylidene indanone lead molecule 💊
  20. A promising anticancer and antimalarial component from the leaves of Bidens pilosa 🌿

Conclusion

Dr. Arvind Singh Negi is an exemplary candidate for the Outstanding Scientist Award. His pioneering work in medicinal chemistry, along with his dedication to advancing cancer therapeutics through innovative research, positions him as a leader in the field. With strategic enhancements in collaboration and outreach, his impact could extend even further, benefiting both scientific communities and public health.

 

 

Yuan Ma | Cell Death Pathway | Best Researcher Award

Published on by Cell Biologist

Prof Yuan Ma | Cell Death Pathway | Best Researcher Award

Prof Yuan Ma , Department of Respiratory and Critical Care Medicine, The First Affiliated Hospital of Nanjing Medical University , China

Yuan Ma is a prominent Professor in the Department of Respiratory and Critical Care Medicine at The First Affiliated Hospital of Nanjing Medical University, China. With a medical background and a focus on bronchial asthma, Dr. Ma has made significant contributions to understanding the mechanisms of airway inflammation and remodeling. Through extensive research, he aims to identify novel molecular targets for asthma therapies. His work has been recognized internationally, underscoring his dedication to advancing clinical applications in respiratory medicine.

Publication Profile

Scopus

Strengths for the Award

  1. Extensive Research Experience: Yuan Ma has a robust academic background as a Professor in Respiratory and Critical Care Medicine. His focus on airway inflammation and remodeling in asthma is critical, given the increasing prevalence of respiratory diseases.
  2. Publication Record: With 25 articles in domestic journals and 13 in international journals, his publication record demonstrates both local and global recognition of his work. Notable articles in high-impact journals underscore the significance and relevance of his research.
  3. Innovative Contributions: Ma’s identification of necroptosis-related targets in asthma and the discovery of potential therapeutic compounds indicate significant advancements in the understanding and treatment of asthma, contributing to both academic knowledge and clinical practice.
  4. Grant Funding: Successfully presiding over projects funded by the National Natural Science Foundation of China highlights his ability to secure funding for impactful research, a crucial aspect of a successful research career.
  5. Patents: The issuance of 13 patents illustrates his innovative capacity and the potential for practical applications of his research findings.

Areas for Improvement

  1. Broader Collaborations: While Ma has made significant contributions, fostering collaborations with researchers from diverse fields could enhance interdisciplinary insights and expand the impact of his work.
  2. Professional Memberships: Engaging in professional organizations could provide networking opportunities and enhance visibility in the research community, further strengthening his position.
  3. Public Outreach: Increasing public engagement and dissemination of research findings could elevate awareness about asthma and his innovations, potentially leading to broader societal impact.

Education 

Dr. Yuan Ma obtained his medical degree from a prestigious institution, followed by specialized training in respiratory medicine. He completed his PhD with a focus on airway diseases, where he gained insights into the cellular and molecular mechanisms underlying asthma. Throughout his academic journey, Dr. Ma has cultivated a robust foundation in both clinical practice and research methodology, allowing him to bridge the gap between laboratory findings and patient care. His continuous pursuit of knowledge in respiratory health has led him to engage in various professional development opportunities, enhancing his expertise and contributing to his role as a leader in his field.

Experience 

Dr. Yuan Ma has extensive experience in both clinical and research settings, spanning over a decade. He has presided over significant research projects funded by the National Natural Science Foundation of China, exploring the pathogenesis of asthma and potential therapeutic interventions. His impressive track record includes 25 publications in national journals and 13 in international peer-reviewed journals, showcasing his commitment to advancing respiratory medicine. As a professor, he mentors medical students and residents, fostering the next generation of researchers and clinicians. His collaborative work with national and international peers has enriched his research, contributing to innovative approaches in asthma treatment. Additionally, his contributions to patent development demonstrate his drive to translate research findings into practical applications for better patient outcomes.

Research Focus 

Dr. Yuan Ma’s research primarily focuses on the mechanisms of airway inflammation and remodeling in bronchial asthma. He investigates necroptosis-related biomarkers and their regulatory mechanisms, aiming to identify novel therapeutic targets. His work encompasses exploring molecular compounds that can effectively modulate these targets, enhancing asthma diagnosis and treatment options. Dr. Ma’s innovative studies delve into the role of oxidative stress and MAPK signaling pathways in airway smooth muscle cell behavior. By examining the intricate interactions within the airway microenvironment, he seeks to uncover underlying processes that contribute to asthma exacerbations. His research has significant implications for developing targeted therapies, addressing the unmet needs of asthma patients, and ultimately improving clinical outcomes in respiratory medicine.

Publications Top Notes

  1. Screening, identification and targeted intervention of necroptotic biomarkers of asthma. 📄
  2. Caffeic acid phenethyl ester alleviates asthma by regulating the airway microenvironment via the ROS-responsive MAPK/Akt pathway. 🌱
  3. Morin Attenuates Ovalbumin-induced Airway Inflammation by Modulating Oxidative Stress-responsive MAPK Signaling. 🩺
  4. A case of male primary pulmonary choriocarcinoma. 🦠
  5. Implication of dendritic cells in lung diseases: immunological role of Toll-like receptor 4. 🔬
  6. Glomus tumors of the trachea: 2 case reports and a review of the literature. 📚
  7. Diosmetin prevents TGF-β1-induced epithelial-mesenchymal transition via ROS/MAPK signaling pathways. 🧬
  8. SARS-CoV-2 in the pancreas and the impaired islet function in COVID-19 patients. 🦠
  9. Characteristics of H7N9 avian influenza pneumonia: a retrospective analysis of 17 cases. 📊
  10. Galangin attenuates airway remodeling by inhibiting TGF-β1-mediated ROS generation and MAPK/Akt phosphorylation in asthma. 🌿
  11. Melatonin modulates airway smooth muscle cell phenotype by targeting the STAT3/Akt/GSK-3β pathway in experimental asthma. 🌙
  12. Single-agent Maintenance Therapy for Advanced Non-small Cell Lung Cancer: A Systematic Review and Bayesian Network Meta-analysis. 🧑‍⚕️
  13. Effect of diosmetin on airway remodeling in a murine model of chronic asthma. 🐭

Conclusion

Yuan Ma’s exceptional research contributions in understanding and treating asthma position him as a strong candidate for the Best Researcher Award. His extensive publication record, innovative findings, and successful grant applications reflect a commitment to advancing respiratory medicine. Addressing areas for improvement could further enhance his profile and influence in the field. Overall, Ma’s achievements warrant recognition, and he is well-suited for this prestigious award.